November 22, 2021 Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease

Today, Biogen and Eisai announced that the Journal of the American Medical Association (JAMA) Neurology published a peer-reviewed paper about findings around amyloid-related imaging abnormalities (ARIA) in the Phase 3 trials of ADUHELM™ (aducanumab-avwa). The publication notes that the importance of the manuscript is, “The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that occur with treatment with aducanumab, an amyloid-β (Aβ)-targeting monoclonal antibody, in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia.”  

 

The combined studies consisted of a total of 3,285 participants with Alzheimer’s disease who received 1 or more doses of placebo (n=1087) or aducanumab (n=2198; 2752 total person-years of exposure) during the placebo-controlled period. 

 

The complete publication is available on the JAMA Neurology website 

 

Type Press Release

Date Released November 22, 2021

RECENT RELEASES
Dec 1, 2021

Eisai Inc. announced today that new data on its antiepileptic drug FYCOMPA® (perampanel) CIII will be presented at the 75th American Epilepsy Society (AES) Annual Meeting to be held from December...

Nov 22, 2021

Media Statement November 22, 2021 Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease...

Nov 11, 2021

Cambridge, Mass. – November 11, 2021– Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced that data from approximately 7,000 plasma samples from more than 1,800 patients in...

Alerts - Release page
SUBSCRIBE TO OUR NEWS
* Required Fields